A reappraisal of Gaucher disease-diagnosis and disease management algorithms

American Journal of Hematology

Volumn 86, Issue 1, 2011, Pages 110-115

  Mistry, Pramod K ^a   Cappellini, Maria Domenica ^b   Lukina, Elena ^c   Özsan, Hayri ^d   Mach Pascual, Sara ^e   Rosenbaum, Hanna ^f   Helena Solano, Maria ^g   Spigelman, Zachary ^h,i   Villarrubia, Jesús ^j   Watman, Nora Patricia ^k   Massenkeil, Gero ^l  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^d DOKUZ EYLUL UNIVERSITY   (Turkey)

^e Hôpital Cantonal   (Switzerland)

^f TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^g San Jose Hospital   (Colombia)

^h Hematology Division   (United States)

ⁱ NEW ENGLAND BAPTIST HOSPITAL   (United States)

^j HOSPITAL RAMÓN Y CAJAL   (Spain)

^k HOSPITAL RAMOS MEJÍA   (Argentina)

^l Klinik für Anästhesiologie Intensiv Notfall und Schmerzmedizin   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CHEMOKINE; CHEMOKINE CCL18; CHITOTRIOSIDASE; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE; FERRITIN; GLUCOSYLCERAMIDASE; HIGH DENSITY LIPOPROTEIN; IMIGLUCERASE; LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ALGORITHM; BONE BIOPSY; CONFERENCE PAPER; DELAYED DIAGNOSIS; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME REPLACEMENT; GAUCHER DISEASE; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SPLENOMEGALY;

ALGORITHMS; DISEASE MANAGEMENT; GAUCHER DISEASE; HUMANS;

EID: 78650352199     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21888     Document Type: Conference Paper

References (73)

1. Beutler E, Grabowski GA. Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. New York, NY: McGraw-Hill; 2001. pp 3635-3668.
2. Zimran A, Altarescu G, Rudensky B, et al. Survey of hematological aspects of Gaucher disease. Hematology 2005; 10: 151-156.
3. Cox TM, Schofield JP. Gaucher's disease: Clinical features and natural history. Baillieres Clin Haematol 1997; 10: 657-689.
4. Grabowski GA. Gaucher disease: Gene frequencies and genotype/phenotype correlations. Genet Test 1997; 1: 5-12.
5. Horowitz M, Pasmanik-Chor M, Borochowitz Z, et al. Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population. Hum Mutat 1998; 12: 240-244.
6. Charrow J, Andersson HC, Kaplan P, et al. The Gaucher registry: Demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000; 160: 2835-2843.
7. Mistry P, Germain DP. Phenotype variations in Gaucher disease. Rev Med Interne 2006; 27( Suppl 1): S3-S10.
8. Mistry PK, Sadan S, Yang R, et al. Consequences of diagnostic delays in type 1 Gaucher disease: The need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol 2007; 82: 697-701.
9. Taddei TH, Kacena KA, Yang M, et al. The under-recognized progressive nature of N370S Gaucher disease and high risk of cancer in 403 patients. Am J Hematol 2009; 84: 208-214.
10. Kaplan P, Andersson HC, Kacena KA, Yee JD. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 2006; 160: 603-608.
11. Zimran A, Kay A, Gelbart T, et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 1992; 71: 337-353.
12. Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: A report from the Gaucher Registry. Am J Med 2002; 113: 112-119.
13. Weinreb N, Barranger J, Packman S, et al. Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet 2007; 71: 576-588.
14. Wenstrup RJ, Kacena KA, Kaplan P, et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 2007; 22: 119-126.
15. Charrow J, Dulisse B, Grabowski GA, Weinreb NJ. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 2007; 71: 205-211.
16. Sims KB, Pastores GM, Weinreb NJ, et al. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: Results of a 48-month longitudinal cohort study. Clin Genet 2008; 73: 430-440.
17. Mistry PK, Deegan P, Vellodi A, et al. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: Effect on incidence of avascular necrosis. Br J Haematol 2009; 147: 561-570.
18. Elstein D, Cohn GM, Wang N, et al. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease. Blood Cells Mol Dis. 2010 Aug 18. [Epub ahead of print]
19. US National Institutes of Health. NCT01132690: A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease; NCT00712348: Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase; NCT00376168: A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease; NCT00962260: Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease. Available at: Last accessed Oct 2010.
20. Zavesca Summary of Product Characteristics Accessible at: Last accessed October 2010.
21. Weinreb NJ, Barranger JA, Charrow J, et al. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol 2005; 80: 223-229.
22. Lukina E, Watman N, Arreguin EA, et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 2010; 116: 893-899.
23. Lukina E, Watman N, Avila Arreguin E, et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: Two-year results of a Phase 2 study. Blood. 2010 Aug 16. [Epub ahead of print]
24. Mistry P, Germain DP. Therapeutic goals in Gaucher disease. Rev Med Interne 2006; 27( Suppl 1): S30-S38.
25. Hughes D, Cappellini MD, Berger M, et al. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol 2007; 138: 676-686.
26. Scott SA, Edelmann L, Liu L, et al. Experience with carrier screening and prenatal diagnosis for sixteen Ashkenazi Jewish genetic diseases. Hum Mutat. 2010 Jul 29. [Epub ahead of print]
27. Lee RE. The pathology of Gaucher disease. In: Desnick RJ, Grabowski GA, editors. Gaucher Disease: A Century of Delineation and Research. New York, NY: Alan R Liss Inc.; 1982. pp 177-217.
28. Shiran A, Brenner B, Laor A, Tatarsky I. Increased risk of cancer in patients with Gaucher disease. Cancer 1993; 72: 219-224.
29. Rosenbloom BE, Weinreb NJ, Zimran A, et al. Gaucher disease and cancer incidence: A study from the Gaucher Registry. Blood 2005; 105: 4569-4572.
30. Zimran A, Liphshitz I, Barchana M, et al. Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis 2005; 34: 197-200.
31. de Fost M, Vom Dahl S, Weverling GJ, et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 2006; 36: 53-58.
32. Hughes DA. Enzyme, substrate and myeloma in Gaucher disease. Amer J Hematol 2009; 84: 199-201.
33. Israel National Cancer Registry (Israel). Available at: Cancer Statistics. Last accessed October 2010.
34. Kadir RA, Kingman CE, Chi C, et al. Screening for factor XI deficiency amongst pregnant women of Ashkenazi Jewish origin. Haemophilia 2006; 12: 625-628.
35. Costello R, O'Callaghan T, Sébahoun G. Gaucher disease and multiple myeloma. Leuk Lymphoma 2006; 47: 1365-1368.
36. Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004; 41(4 Suppl 5 ): 4-14.
37. Cox TM, Aerts JM, Belmatoug N, et al. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis 2008; 31: 319-336.
38. Stein P, Malhotra A, Haims A, et al. Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy. J Inherit Metab Dis. 2010 Aug 4. [Epub ahead of print]
39. Charrow J, Esplin JA, Gribble TJ, et al. Gaucher disease: Recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med 1998; 158: 1754-1760.
40. Sidransky E. Gaucher disease: Complexity in a "simple" disorder. Mol Genet Metab 2004; 83: 6-15.
41. Shenjere P, Roy A, Eyden B, Banerjee SS. Pseudo-Gaucher cells in multiple myeloma. Int J Surg Pathol 2008; 16: 176-179.
42. Saito T, Usui N, Asai O, et al. Pseudo-Gaucher cell proliferation associated with myelodysplastic syndrome. Int J Hematol 2007; 85: 350-353.
43. Büsche G, Majewski H, Schlué J, et al. Frequency of pseudo-Gaucher cells in diagnostic bone marrow biopsies from patients with Ph-positive chronic myeloid leukaemia. Virchows Arch 1997; 430: 139-148.
44. Links TP, Karrenbeld A, Steensma JT, et al. Fatal respiratory failure caused by pulmonary infiltration by pseudo-Gaucher cells. Chest 1992; 101: 265-266.
45. Dunn P, Kuo MC, Sun CF. Pseudo-Gaucher cells in mycobacterial infection: A report of two cases. J Clin Pathol 2005; 58: 1113-1114.
46. Bain BJ, Lee L. Pseudo-Gaucher cells in sickle cell anemia. Amer J Hematol 2010; 85: 435.
47. Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1: Revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 2004; 41(4 Suppl 5 ): 15-22.
48. Aerts JM, Breemen MJ, Bussink AP, et al. Biomarkers for lysosomal storage disorders: Identification and application as exemplified by chitotriosidase in Gaucher disease. Acta Paediatr Suppl 2008; 97: 7-14.
49. Stein P, Yu H, Jain D, Mistry PK. Hyperferritinemia and iron overload in type 1 Gaucher disease. Am J Hematol 2010; 85: 472-476.
50. Andersson HC, Charrow J, Kaplan P, et al.;International Collaborative Gaucher Group U.S. Regional Coordinators. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med 2005; 7: 105-110.
51. Di Rocco M, Giona F, Carubbi F, et al. A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica 2008; 93: 1211-1218.
52. Weinreb NJ, Cappellini MD, Cox TM, et al. A validated disease severity scoring system for adults with type 1 Gaucher disease. Genet Med 2010; 12: 44-51.
53. Davies EH, Surtees R, DeVile C, et al. A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease. J Inherit Metab Dis 2007; 30: 768-782.
54. Vellodi A, Tylki-Szymanska A, Davies EH, et al. Management of neuronopathic Gaucher disease: Revised recommendations. J Inherit Metab Dis 2009; 32: 660-664.
55. Weinreb NJ, Deegan P, Kacena KA, et al. Life expectancy in Gaucher disease type 1. Am J Hematol 2008; 83: 896-900.
56. Weinreb N, Taylor J, Cox T, et al. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Amer J Hematol 2008; 83: 890-895.
57. Grabowski G, Kacena K, Hollak CE, et al. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet Med 2009; 11: 92-100.
58. Mistry PK, Sirrs S, Chan A, et al. Pulmonary hypertension in type 1 Gaucher's disease: Genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 2002; 77: 91-98.
59. Amato D, Stachiw T, Clarke JT, Rivard GE. Gaucher disease: Variability in phenotype among siblings. J Inherit Metab Dis 2004; 27: 659-669.
60. Goker-Alpan O, Hruska KS, Orvisky E, et al. Divergent phenotypes in Gaucher disease implicate the role of modifiers. J Med Genet 2005; 42: e37.
61. Bultron G, Kacena K, Pearson D, et al. The risk of Parkinson's disease in type 1 Gaucher disease. J Inherit Metab Dis 2010; 33: 167-173.
62. Goker-Alpan O, Lopez G, Vithayathil J, et al. The spectrum of Parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 2008; 65: 1353-1357.
63. Aharon-Peretz J, Badarny S, Rosenbaum H, et al. Mutations in the glucocerebrosidase gene and Parkinson disease: Phenotype-genotype correlation. Neurology 2005; 65: 1460-1461.
64. Elleder M. Glucosylceramide transfer from lysosomes-The missing link in molecular pathology of glucosylceramidase deficiency: A hypothesis based on existing data. J Inherit Metab Dis 2006; 29: 707-715.
65. Torloni MR, Franco K, Sass N. Gaucher's disease with myocardial involvement in pregnancy. Sao Paulo Med J 2002; 120: 90-92.
66. Capablo JL, Saenz de Cabezón A, Fraile J, et al.Spanish Group on Gaucher disease. Neurological evaluation of patients with Gaucher disease diagnosed as type 1. J Neurol Neurosurg Psychiatry 2008; 79: 219-222.
67. Stone DL, Carey WF, Christodoulou J, et al. Type 2 Gaucher disease: The collodion baby phenotype revisited. Arch Dis Child Fetal Neonatal Ed 2000; 82: F163-F166.
68. Mistry PK, Liu J, Yang M, et al. GBA1 deficiency in the mouse recapitulates Gaucher disease displaying system-wide cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci USA, in press.
69. McEachern KA, Nietupski JB, Chuang WL, et al. AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease. J Gene Med 2006; 8: 719-729.
70. Mu TW, Ong DS, Wang YJ, et al. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 2008; 134: 769-781.
71. McEachern KA, Fung J, Komarnitsky S, et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 2007; 91: 259-267.
72. Chamoles NA, Blanco M, Gaggioli D, Casentini C. Gaucher and Niemann-Pick diseases-Enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards. Clin Chim Acta 2002; 317: 191-197.
73. Olivova P, Cullen E, Titlow M, et al. An improved high-throughput dried blood spot screening method for Gaucher disease. Clin Chim Acta 2008; 398: 163-164.